11 Result(s)
within
Ralph Wäsch
Cancer Research
-
Article
Open AccessLong-term follow-up of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation after primary induction failure
Primary induction failure (PIF) in acute myeloid leukemia (AML) patients is associated with poor outcome, with allogeneic hematopoietic stem cell transplantation (HCT) being the sole curative therapeutic optio...
-
Article
Open AccessHyaluronic acid–GPRC5C signalling promotes dormancy in haematopoietic stem cells
Bone marrow haematopoietic stem cells (HSCs) are vital for lifelong maintenance of healthy haematopoiesis. In inbred mice housed in gnotobiotic facilities, the top of the haematopoietic hierarchy is occupied b...
-
Article
Open AccessEx vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma
Multiple myeloma (MM) remains an incurable hematologic malignancy which ultimately develops drug resistance and evades treatment. Despite substantial therapeutic advances over the past years, the clinical fail...
-
Article
Open AccessMultidisciplinary tumor boards and their analyses: the yin and yang of outcome measures
The standard to ensure utmost cancer treatment is a prerequisite in national cancer plans for comprehensive cancer centers (CCCs) and ensured through multidisciplinary tumor boards (MTBs). Despite these being ...
-
Article
Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia
-
Article
PIM1 inhibition effectively enhances plerixafor-induced HSC mobilization by counteracting CXCR4 upregulation and blocking CXCL12 secretion
-
Article
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)
Multiple myeloma is a disease typical of the elderly, and, because of the increase in life expectancy of the general population, its incidence is expected to grow in the future. Elderly patients represent a pa...
-
Article
Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Nat. Med. 24, 282–291 (2018); published online 12 February 2018; corrected after print 6 March 2018 In the version of this article initially published, Omid Shah's name was misspelled as Omid Sha. The error ha...
-
Article
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Combining the kinase inhibitor sorafenib with allogeneic stem cell transplantation boosts immune responses against a subtype of acute myelogenous leukemia, suggesting potential clinical benefit.
-
Chapter
Ruxolitinib
Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of JAK1 and JAK2. Ruxolitinib has been approved for the treatment of myelofibrosis, which is characterized, biologi...
-
Chapter
Pomalidomide
Pomalidomide (originally CC-4047 or 3-amino-thalidomide) is a derivative of thalidomide that is antiangiogenic and also acts as an immunomodulator. Pomalidomide, as the newest immunomodulatory agent (IMiD), ha...
